Invention is an essential feature of business. The best inventions are created when you mix talented people playing to their strengths in an environment of open collaboration, working in partnership with clients and suppliers with a clear focus on commercial goals.
Exciting and varied work that makes a difference. A collaborative culture where you can take on complex technical challenges and deliver commercial impact. That's life at TTP.
The satellite and telecoms industries have committed to the future convergence of terrestrial and non-terrestrial telecommunications networks. A world of global hybrid connectivity based on 5G standards is coming into sight, and so is a new industry ecosystem.
Many generics companies have experienced the challenges of getting a “complex generic” to market firsthand. But, argues David Cottenden, there are device strategies to stack the odds in your favour…
The revolution in domestic robotics did not happen as Bill Gates predicted. But a decade of progress means that we can ask what vision for domestic robotics could eventually satisfy the cost, performance and safety requirements of the consumer.
Pathology is going digital and novel quantitative imaging approaches will take diagnostic power to the next level while creating opportunities for automation in the multi-billion tissue diagnostics industry. Alexander Carr reviews steps towards quantification in 2019.
On 13th March, a group of leading medical device development companies from Cambridge was asked by the UK Government to assist in the rapid development and manufacture of ventilators to meet increased hospital requirements, caused by COVID-19.
TTP plc (TTP), a leading independent technology and product development company, has today announced it has entered into a partnership with ME SOLshare Ltd (‘SOLshare’), a social enterprise that has created a new approach to distributing and trading affordable solar electricity across peer-topeer micro-grids. By making improvements to the SOLbox trading platform, the collaboration aims to increase the supply of sustainable electrical power to communities in developing countries.
TTP plc (TTP), a leading independent technology and product development company, today announced it has established a partnership with NHS Highland and The University of the Highlands and Islands, to use clinical data interpretation and machine learning algorithms to predict which patients with atrial fibrillation (AF) are able to be successfully treated using electrical cardioversion (ECV).
TTP and DiaSorin have signed an exclusive licence and technology transfer agreement. DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.
